$47.69
0.54[1.15%]
At close: Apr 23
$47.69
0[0.00%]
After Hours: 4:00PM EDT
Latest News for Sanofi Stock (NASDAQ:SNY)
Sanofi Stock (NASDAQ: SNY)
Categories: All
Tuesday, April 23, 2024
Monday, April 22, 2024
Sunday, April 21, 2024
Wednesday, April 17, 2024
- Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His PickVandana Singh - 6 days ago
- Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 YearsVandana Singh - 6 days ago
- Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease ActivityVandana Singh - 6 days ago
- Sanofi's CD40L Antibody: New 48-Week Phase 2 Data Support Frexalimab's Potential For High Sustained Efficacy In Multiple SclerosisBenzinga Newsdesk - 6 days ago
Monday, April 15, 2024
Friday, April 12, 2024
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Thursday, April 04, 2024
Wednesday, April 03, 2024
Wednesday, March 27, 2024
- What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?Vandana Singh - Mar 27, 2024, 1:42PM
- How Is The Market Feeling About Sanofi?Benzinga Insights - Mar 27, 2024, 11:45AM
- Dr Reddy's Entered Into Exclusive Distribution Partnership With Sanofi Healthcare IndiaCharles Gross - Mar 27, 2024, 6:10AM
Tuesday, March 26, 2024
Friday, March 08, 2024
Wednesday, February 28, 2024
Monday, February 26, 2024
- Peru To Declare Emergency In Parts Of Country For Increase In Dengue CasesBenzinga Newsdesk - Feb 26, 2024, 12:55PM
- Reported Saturday, Sanofi's Rilzabrutinib Phase 2 Results Demonstrate Rapidly Reduced Itch Severity And Significantly Improved Disease Activity In Adults With Chronic Spontaneous UrticariaBenzinga Newsdesk - Feb 26, 2024, 3:28AM
Friday, February 23, 2024
Tuesday, February 20, 2024
Friday, February 16, 2024
- Denali Therapeutics Was Informed By Its Partner Sanofi That The Phase 2 HIMALAYA Study Evaluating SAR443820/DNL788 In Participants With Amyotrophic Lateral Sclerosis Did Not Meet The Primary Endpoint Of Change In Als Functional Rating Scale-Revised - 8KBenzinga Newsdesk - Feb 16, 2024, 8:07AM
- Regeneron And Sanofi Announce Japan First In The World To Approve Dupixent® For Chronic Spontaneous UrticariaBenzinga Newsdesk - Feb 16, 2024, 2:14AM
Thursday, February 08, 2024
Monday, February 05, 2024
Friday, February 02, 2024
Thursday, February 01, 2024
- Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Feb 1, 2024, 1:17PM
- Sanofi shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY24 EPS guidance.Benzinga Newsdesk - Feb 1, 2024, 11:58AM
- French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia DrugsVandana Singh - Feb 1, 2024, 9:24AM
- Privately Held-Graviton Bioscience Announces A Strategic Investment From Sanofi, Deal Terms Were Not DisclosedBenzinga Newsdesk - Feb 1, 2024, 7:43AM
- Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The YearShanthi Rexaline - Feb 1, 2024, 7:27AM
- MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAvi Kapoor - Feb 1, 2024, 5:10AM
- Earnings Scheduled For February 1, 2024Benzinga Insights - Feb 1, 2024, 5:03AM
- Sanofi Appoints François-Xavier Roger As Chief Financial Officer, Effective April 1, 2024Benzinga Newsdesk - Feb 1, 2024, 1:55AM
- Sanofi Expects 2024 Business EPS To Remain Roughly Stable; Applying Average January 2024 Exchange Rates, The Currency Is Estimated Between -3.5% To -4.5%Benzinga Newsdesk - Feb 1, 2024, 1:53AM
- Sanofi Q4 Adj. EPADS $0.89 Misses $1.50 Estimate, Sales $11.75B Miss $12.26B EstimateBenzinga Newsdesk - Feb 1, 2024, 1:49AM
Wednesday, January 31, 2024
Monday, January 29, 2024
- Synthekine Collaborates With Sanofi To Develop Selective IL-10 Agonists For Treatment Of Inflammatory Diseases; Synthekine To Receive $40M Payment; Eligible For Additional Payments And RoyaltiesBenzinga Newsdesk - Jan 29, 2024, 8:09AM
- Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?Shanthi Rexaline - Jan 29, 2024, 5:51AM
Friday, January 26, 2024
Thursday, January 25, 2024
Tuesday, January 23, 2024
- French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2BVandana Singh - Jan 23, 2024, 8:00AM
- Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx ProjectBenzinga Neuro - Jan 23, 2024, 7:46AM
- Morgan Stanley Initiates Coverage On Sanofi with Equal-Weight Rating, Announces Price Target of $55Benzinga Newsdesk - Jan 23, 2024, 6:47AM
- Inhibrx Sells INBRX-101 To Sanofi For Up To $2.2B, Spins Off New Company With All Non-101 Assets And LiabilitiesBenzinga Newsdesk - Jan 23, 2024, 1:09AM